531 related articles for article (PubMed ID: 31811017)
1. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
[TBL] [Abstract][Full Text] [Related]
2. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
8. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
Perrot A; Monjanel H; Bouabdallah R; Quittet P; Sarkozy C; Bernard M; Stamatoullas A; Borel C; Bouabdallah K; Nicolas-Virelizier E; Fournier M; Morschhauser F; Brice P;
Haematologica; 2016 Apr; 101(4):466-73. PubMed ID: 26768687
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
10. A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.
Wei W; Lin Y; Song Z; Xiao W; Chen L; Yin J; Zhou Y; Barta SK; Petrus M; Waldmann TA; Yang Y
Clin Cancer Res; 2020 Aug; 26(15):4093-4106. PubMed ID: 32299816
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
[TBL] [Abstract][Full Text] [Related]
12. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
15. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
Salihoglu A; Elverdi T; Karadogan I; Paydas S; Ozdemir E; Erdem G; Karadurmus N; Akyol G; Kaynar L; Yegin Z; Sucak G; Ozkocaman V; Topcuoglu P; Ozcan M; Birtas E; Goker H; Baslar Z; Ferhanoglu B
Ann Hematol; 2015 Mar; 94(3):415-20. PubMed ID: 25231929
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Vaklavas C; Forero-Torres A
Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
[TBL] [Abstract][Full Text] [Related]
19. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]